Arcutis Biotherapeutics (NASDAQ:ARQT) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Arcutis Biotherapeutics (NASDAQ:ARQT) released its earnings results on Wednesday. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05, FiscalAI reports. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. The company had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million.

Here are the key takeaways from Arcutis Biotherapeutics’ conference call:

• Positive Sentiment: Q2 net product revenue rose 59% year over year to $129.9 million, driven by strong ZORYVE demand and improved gross-to-net deductions. The company raised its full-year 2026 revenue guidance to $525 million–$540 million from $480 million–$495 million.
• Positive Sentiment: ZORYVE received FDA approval for plaque psoriasis in children as young as two, while the FDA accepted the application for atopic dermatitis in infants down to three months, with a February 2027 decision expected. Management views the pediatric indications as significant unmet-need opportunities.
• Positive Sentiment: Arcutis is investing in growth through expanded dermatology, primary-care and pediatric sales teams, direct-to-consumer marketing, a virtual dermatology platform and AI-enabled prescription fulfillment tools. The company expects the dermatology expansion to support second-half 2026 growth, with primary-care and pediatric contributions beginning in 2027.
• Positive Sentiment: The company reported $15 million of net income and $12.6 million of operating cash flow in Q2, ending the quarter with $238.9 million in cash and marketable securities. Management expects positive cash flow for the remainder of 2026 while continuing to fund pipeline and commercial investments.
• Negative Sentiment: Chief Commercial Officer Todd Edwards will leave later this month to pursue other opportunities, creating a leadership transition. Arcutis appointed Rob Lisicky as interim CCO while it conducts a permanent search, although management characterized the commercial team and transition plan as strong.

Arcutis Biotherapeutics Trading Up 5.0%

Shares of ARQT stock traded up $1.35 during trading hours on Thursday, hitting $28.45. The company had a trading volume of 412,350 shares, compared to its average volume of 1,536,907. The stock has a market capitalization of $3.56 billion, a PE ratio of -947.55 and a beta of 1.49. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.68 and a quick ratio of 2.46. Arcutis Biotherapeutics has a fifty-two week low of $13.69 and a fifty-two week high of $31.77. The company’s fifty day moving average is $25.87 and its 200 day moving average is $24.68.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong earnings and revenue growth: Second-quarter revenue reached $129.9 million, up 59% year over year and 23% from the first quarter. Earnings of $0.11 per share exceeded analyst estimates of $0.06-$0.09 and improved from a $0.13-per-share loss a year earlier. Arcutis Second Quarter 2026 Results
• Positive Sentiment: 2026 outlook raised: Arcutis lifted full-year net product sales guidance to $525 million-$540 million, reflecting continued demand for ZORYVE. The company also reported positive operating cash flow for the quarter, supporting confidence in its commercial growth trajectory. Arcutis Business Update
• Positive Sentiment: Additional ZORYVE opportunities: The FDA approved ZORYVE cream 0.3% for plaque psoriasis patients as young as two. Regulators also accepted an application for use in infants ages three to 24 months with mild-to-moderate atopic dermatitis, with a decision expected by February 23, 2027. Enrollment is complete in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. ZORYVE Regulatory and Pipeline Update
• Positive Sentiment: Analyst price-target increase: Needham raised its price target for ARQT from $36 to $40 and maintained a Buy rating. The revision reinforces the bullish view that ZORYVE’s commercial performance can support further upside. Benzinga analyst update
• Neutral Sentiment: Insider transactions were administrative: Three executives sold a combined 6,560 shares for approximately $171,000. The sales occurred under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a limited bearish signal. SEC insider filing

Insider Buying and Selling at Arcutis Biotherapeutics

In other news, Director Sue-Jean Lin sold 4,946 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.38, for a total value of $120,583.48. Following the completion of the transaction, the director owned 27,567 shares in the company, valued at approximately $672,083.46. This trade represents a 15.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Todd Watanabe sold 4,375 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.12, for a total value of $114,275.00. Following the sale, the insider owned 717,203 shares of the company’s stock, valued at approximately $18,733,342.36. The trade was a 0.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 16,894 shares of company stock valued at $422,044 in the last quarter. Corporate insiders own 9.40% of the company’s stock.

Hedge Funds Weigh In On Arcutis Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARQT. Global Retirement Partners LLC bought a new stake in Arcutis Biotherapeutics during the fourth quarter worth approximately $35,000. NewEdge Advisors LLC boosted its stake in shares of Arcutis Biotherapeutics by 209.0% during the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock worth $45,000 after acquiring an additional 1,045 shares in the last quarter. Truvestments Capital LLC grew its holdings in shares of Arcutis Biotherapeutics by 114.2% in the 4th quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock worth $87,000 after acquiring an additional 1,606 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Arcutis Biotherapeutics during the second quarter worth $145,000. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Arcutis Biotherapeutics by 4,562.5% during the second quarter. Russell Investments Group Ltd. now owns 11,190 shares of the company’s stock valued at $157,000 after purchasing an additional 10,950 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on ARQT shares. Wall Street Zen raised Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Wednesday, June 24th. Needham & Company LLC lifted their price target on Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. Guggenheim lifted their price objective on Arcutis Biotherapeutics from $35.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $38.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.57.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.